RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Alan R. Katz to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Back to Details
This is a "connection" page, showing publications Alan R. Katz has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Alan R. Katz
Connection Strength
0.378
Hydroxymethylglutaryl-CoA Reductase Inhibitors
  1. Dahl L, Schultz A, McGibbon E, Brownlie J, Cook C, Elbarouni B, Katz A, Nguyen T, Sawatzky JA, Sinclaire M, Throndson K, Prior HJ, Fransoo R. Cardiovascular Medication Use and Long-Term Outcomes of First Nations and Non-First Nations Patients Following Diagnostic Angiography: A Retrospective Cohort Study. J Am Heart Assoc. 2019 08 20; 8(16):e012040.
    View in: PubMed
    Score: 0.163
  2. Brown F, Singer A, Katz A, Konrad G. Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. Can Fam Physician. 2017 Nov; 63(11):e495-e503.
    View in: PubMed
    Score: 0.144
  3. Raymond CB, Morgan SG, Katz A, Kozyrskyj AL. A population-based analysis of statin utilization in British Columbia. Clin Ther. 2007 Sep; 29(9):2107-19.
    View in: PubMed
    Score: 0.071
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support